Santen Pharmaceutical Co., Ltd.
9.95
EUR
+0.20
(+2.05%)
Santen Pharmaceutical Co., Ltd.
TG:SZD
(Tradegate Exchange)
Recent
price
9.95
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.- Similar Companies
- Business
- Santen Pharmaceutical Co., Ltd. (4536.T) specializes in the research, development, manufacturing, marketing, and sales of prescription pharmaceuticals, over-the-counter products, and medical devices focused on ophthalmology; its core offerings address glaucoma (including brands like SETANEO Ophthalmic Solution 0.002% launched in Japan in October 2025, DIQUAS LX Ophthalmic Solution 3% for dry eye with resumed shipments announced in November 2025), dry eye disease, ocular allergies, uveitis, myopia, meibomian gland dysfunction, pterygium, and retinal diseases such as diabetic macular edema; the company also advances pipelines in ROCK inhibitors via prior licensing with Aerie Pharmaceuticals, VEGF inhibitors like Beovu and Lucentis through an exclusive promotion and distribution agreement with Santen Korea in October 2025, and other innovative therapies targeting angiogenesis and fibrosis. Founded in 1890 and headquartered in Osaka, Japan, Santen operates globally with manufacturing plants in Japan (Hōdatsushimizu, Ishikawa), Finland (Tampere), and China (Suzhou), an R&D center in Ikoma, Nara, Japan, and subsidiaries across more than 60 countries and regions including the United States, Europe (Netherlands, Finland, UK, Spain, Switzerland, Italy, France, Germany, Sweden), Asia (China, South Korea, Taiwan, India, Thailand, Malaysia, Philippines, Singapore, Vietnam, Hong Kong), and others, serving patients, healthcare professionals, and consumers in these markets as the market leader for prescription ophthalmic pharmaceuticals in Japan. Recent strategic developments include an exclusive licensing agreement with RemeGen in August 2025 for RC28-E intravitreal injection (with biologic license application accepted in China for diabetic macular edema in September 2025), a licensing deal with Cloudbreak Pharma in September 2024 for a topical pterygium treatment, a collaboration with SERI announced in December 2025 to advance disease-modifying therapies for major eye diseases, the launch of SETANEO in Japan in October 2025, and an exclusive promotion agreement for Beovu and Lucentis in South Korea in October 2025, alongside ongoing share buybacks completed in November 2025 and treasury share disposals for performance-linked remuneration.
Company News
Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Stock Short Interest Report for September
LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU
Santen Pharmaceutical (OTCMKTS:SNPHY) & Otsuka (OTCMKTS:OTSKY) Financial Review
Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update